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Chapter I 
 
Introduction 
 
In normal healthy animals, the gastrointestinal tracts are colonized by a complex 
microflora containing many different species. A balance of these microorganisms in the 
gastrointestinal tract is important not only in promoting efficient digestion and maximum 
absorption of nutrients, but also in increasing the capacity of the host in excluding 
infectious microorganisms and hence preventing disease (Walter et al., 2003). 
Lactobacilli are common inhabitants of animal gastrointestinal tracts and many 
investigators have reported them to provide various positive health attributes. This group 
of “good” bacteria is generally called probiotics. Therefore, probiotics can be defined as 
living microorganisms that upon ingestion in certain numbers exert health effects beyond 
inherent basic nutrition (Gurner et al., 1998). Naidu et al., 1999 describes probiotics as 
microbial dietary adjuvants that beneficially affect the hosts’ physiology by modulating 
their mucosal and systemic immunity as well as improving the nutritional and microbial 
balance in their intestinal tracts. Probiotics are potentially useful in the management and 
treatment of various gastrointestinal diseases including diarrhea, inflammatory bowel 
disease, and colon cancer (Rolfe, 2000). Enhancement of nonimmunological gut defense 
barrier by probiotics may include maintenance of normal levels of intestinal permeability 
and micro-ecology, which is commonly shifted in the event of intestinal infection by 
pathogenic bacteria.   
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Vertebrate immune system can mount both innate and adaptive immune response in 
the event of infection by pathogenic microorganisms. Many types of immune cells are 
recruited to elicit an immune response and subsequently neutralize the pathogens. These 
cells include epithelial cells, natural killer cells, macrophages, neutrophils, dendritic cells 
and lymphocytes. These cells are quickly activated in the event of infection leading to 
production of an array of humoral mediators. Some may change their physiology and 
become phagocytic, yet others get involved in antibody synthesis and secretion. These 
activated immune cells may provide immediate protection against pathogens or promote 
specific immune responses. Therefore, these cells are useful in the probiotic enhancement 
of immunologic barrier in the animal gastrointestinal tract.   
Probiotics have profound effects on potentiating both arms of immune responses. For 
instance, oral administration of the probiotic, Bifidobacterium breve was shown in mice 
that had been previously challenged with cholera toxin to promote humoral immunity by 
enhancing the secretion of immunoglobulin A (IgA) (Yasui et al., 1999). In an 
investigation conducted by De Simone et al., (1993), bacterial cell wall products were 
demonstrated to be able to not only enhance the proliferation of immune cells but also 
induce the expression of proinflammatory cytokines, which are necessary for the 
maintenance of a stable Th1/Th2 balance.  This delicate balance is important for the host 
immune function as it dictates whether a humoral (antibody production) or a cell- 
mediated (cytotoxic T-cell) response should be mounted (De Simone et al., 1993). 
Therefore, the influence of a probiotic strain of bacteria on the mammalian immune 
system can be easily evaluated through in vitro and in vivo measurement of cytokines, 
immunoglobulin production and lymphocyte proliferation.  
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The use of antibiotics is associated with the emergence of antibiotic-resistant bacteria, 
which have become difficult to control and have exerted adverse effects on the 
consumers of animal products. With the above positive attributes of probiotic bacteria on 
the prevention and disease management, probiotics hold great potential as a better 
alternative to antibiotics in farm animals.  
In this present study, the use of lactic acid-producing bacteria, Lactobacillus 
acidophilus, as a feed supplement in the diet of healthy Holstein calves and its ability to 
modulate their innate and adaptive immune responses was investigated.  
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Chapter II 
 
Literature Review 
 
 
Probiotics 
A “probiotic” by the generally accepted definition, is “a live microbial feed 
supplement, which beneficially affects the host animal by improving its intestinal 
microbial balance” (Fuller, 1989). This definition was broadened by Havenaar and Huis 
in’t Veld (1992) to a “mono or mixed culture of live microorganisms which benefit man 
and animals by improving the properties of their indigenous microflora”. Although the 
definition of probiotics is constantly evolving, they are living microorganisms that confer 
health benefits to their hosts by improving the indigenous microflora (Sanders, 1998; 
Tannock, 1999). A European Commission concerted action program redefined probiotics 
as “a live microbial food ingredient that is beneficial to health” (Salminen et al., 1998). In 
a broadened definition, Naidu et al., (1999) describes probiotics as microbial dietary 
adjuncts that beneficially affect the host physiology by modulating the mucosal and 
systemic immunity as well as improving nutritional and microbial balance in the 
intestinal tract. 
Microflora in animals is extremely important in protecting them against pathogenic 
infections. This fact is evident in the way germ-free animals become susceptible to 
infections in their intestines. While it takes 105 spores of Clostridium botulinum to kill 
mice with functional microflora, only 50 spores are required to kill germ-free mice 
(Wells et al., 1982). 
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In vitro, dozens of microorganisms have been shown to have desirable probiotic 
qualities. However, some ingested bacteria are normally killed in the host stomachs by 
gastric juices. A small number of strains have been shown to colonize the human 
gastrointestinal tract in clinical trial (Crabbe et al., 1968). Some scholars believe this 
colonization is a prerequisite for any health benefits to be conferred. The effect of the 
probiotics on the intestinal ecosystem, may impact the consumer in some beneficial way. 
For a given microorganism to function as an effective probiotic, it must have some 
important properties as in the case of some species of lactobacilli (Reid et al., 1990). The 
organism should be able to: adhere persistently to intestinal epithelial cells and mucus; 
reduce and exclude pathogenic adherence to healthy cells; reproduce in such a manner to 
allow rapid multiplication and colonization; produce reactive agents such as acids, 
hydrogen peroxides and bacteriocins that can hamper pathogen reproduction and 
multiplication; be safe, noncarcinogenic and nonpathogenic; resist various microbicides; 
and form a balanced flora (Reid et al., 1990). 
A number of potential benefits arising from changes to the intestinal milieu through 
the consumption of probiotics have been proposed, including: a) Increased resistance to 
intestinal infections, by pathogen interference, exclusion, and antagonism; b) reduction in 
blood pressure; c) reduction in serum cholesterol concentration; d) maintenance of 
mucosal integrity; e) alleviation of symptoms of lactose intolerance; f) reduction in 
allergy g) stimulation of phagocytosis by peripheral blood leucocytes; h) immune system 
stimulation and modulation in human and animals; i) vaginal and urinary tract health; j) 
modulation of cytokine gene expression; k) adjuvant effect; l) regression of tumors; m) 
and reduction in carcinogens or co-carcinogen production 
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Some probiotics produce metabolic by-products that are antagonistic to establishment 
of pathogenic microorganisms. Strains of Lactobacillus may produce lactic acid and 
hydrogen peroxide that are not only toxic but might aid in inhibition and exclusion of 
potential pathogens (Gilliland and Speck, 1977). Perhaps, surprisingly, despite this 
impressive list of potentially beneficial attributes, probiotics are not commonly part of the 
medical practitioners’ and veterinarians’ armamentarium treatment or preventative 
methods. 
 
The gut mucosal barrier 
The small intestine is constantly exposed not only to food but also to a variety of 
antigens in the life of mammals. These exposures pose challenges to the host because 
some of the antigens may be pathogenic. The bacterial load in the small intestine is 
dynamic and keeps changing both in numbers and types. A well functioning mucosal 
barrier in the gut is important and may help in excluding establishment of pathogenic 
microoragnisms (Janeway et al., 1999). Some antigens are absorbed across the mucosal 
epithelial-cell layer and may be processed in the lysosomes or may be eliminated by the 
mucosal immune system (Isolauri et al., 1993). 
It is well documented that the effect of commensal probiotic bacteria on the immune 
response of their host animals is through their close association with the gut lymphoid 
tissues found in the intestinal mucosa. The gut-associated lymphoid tissues are found in 
specific compartments in the host intestinal tract. The Peyer’s Patches, which are areas 
rich in B-cell lymphoid follicles, are highly organized lymphoid tissues in the wall of the 
small intestine. The Peyer’s Patches are also resident to interfollicular populations of T- 
7cells. Large numbers of lymphoid and myeloid cells aggregate to form the lamina 
propria, which is found to be rich in immunoglobulin-A plasmablasts. The lamina propria 
is found scattered under the gut epithelium. Interspersed within the enterocyte monolayer 
are intraepithelial lymphocytes, which are made up of mostly CD8+ T-cell subsets 
(Janeway et al., 1999). It has been reported by various groups that the quantity and 
quality of immune cells in the Peyer’s Patches and lamina propria compartments depend 
on continuous stimulation provided by endogenous intestinal microflora (Cebra, 1999).  
In an investigation by Crabbe et al. (1968), they demonstrated that colonization of 
germ-free mice with different strains of lactic acid bacteria (LAB) induced the secretion 
of mucosal IgA from both the Peyer’s Patches and lamina propria. Since these LAB are 
also commensal organisms in many animals, they might be able to potentiate various 
indices of hosts’ humoral immune responses when used as dietary supplements. 
The development of probiotics for farm animals is based on the knowledge that gut 
microflora is involved in resistance to disease in mammals (Gill, 1998). In a clinical 
study with human volunteers, Alander et al. (1999) demonstrated that L. rhamnosus GG 
attached to human intestinal mucosa and the attachment persisted for about seven days 
following withdrawal of the probiotics. In a different clinical study, Miller et al., (1993) 
demonstrated that application of the same strain to premature infants did not decrease 
pathogen load even if it colonized the intestines. This investigation suggested that the 
probiotic was poorly antagonistic to pathogenic bacteria in vivo. However, the increased 
likelihood of gastrointestinal infection in infants may be due to immaturity of their gut 
defense barrier. This barrier is important because it forms a protective phase between the 
8infants’ internal environment and the potentially pathogenic factors in the external 
environment (Juntunen et al., 2001).  
Although the mechanisms behind the positive effects of probiotics on the host are not 
well known, one way in which probiotics may augment favorable health outcome on the 
host is by enhancing nonspecific (innate) and antigen-specific (adaptive) immune 
response (Miller et al., 1993; Juntunen et al., 2001). 
 
Immune modulation by probiotics 
Immune modulation by dietary bacteria has continued to be a subject of growing 
interest. Probiotics have been reported to facilitate stabilization of gut microflora and 
hence enhance gut defense against pathogenic microorganisms in a way that is 
nonimmunological (Salminen et al., 1998). They can also enhance immunologic barrier 
of the host intestine (Kaila et al., 1992). Although it is known that immune function tends 
to decline with age, supplementation twice daily with a probiotic Bifidobacterium lactis 
was found to significantly increase and improve various indices of immune function in a 
group of healthy elderly people in a double-blinded trial. The good attributes of the 
bacterial supplementation were observed in this group after about six week of trial time 
(Aruchalam et al., 2000). In other studies, probiotics have been shown to augment the 
humoral arm of adaptive immunity and subsequently enhance the immunologic barrier of 
the intestine (Kaila et al., 1992).  
In the event of their action in animals as immune modulators, probiotics may either 
have up- or down-regulatory effects on various indices of immune response. Live 
probiotic microorganisms may stimulate production of cytokines and therefore enhance 
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natural immune responses (Marin et al., 1997). Intestinal inflammation can be suppressed 
by viable probiotics after oral administration, which makes these microorganisms useful 
in controlling hypersensitivity reactions (Majamaa et al., 1996). 
In another independent investigation on the antiproliferative effects of five strains of 
probiotic bacteria, Pessi et al. (1999) studied the proliferation activity of mononuclear 
cells induced by phytohemagglutin as a mitogen. Proliferation of these cells was carried 
out in the presence or absence of either unheated or heat-treated probiotic homogenates 
from L. rhamnosus GG, B. lactis, or L. acidophilus. They demonstrated that homogenates 
from these bacteria suppressed proliferation of mononuclear cells with mitogen 
treatment. The suppression was observed with both unheated and heat-treated 
homogenates. Their findings suggested that these homogenates might be used to generate 
nonviable food products that are immunologically active.  
Low cost and convenience of administration makes immune modulation via the oral 
route a very desirable treatment. Due to large volumes of antigen required for oral 
immunization, and that exposure to soluble protein antigen may induce oral tolerance, 
researchers are leaning towards the use of microorganisms to induce the desired 
immunity (Wells et al., 1996). The adherence to intestinal epithelium and mucus by 
probiotics may be an integral factor in the stimulation of the host immune system. 
Adhesion assists the bacteria in surviving host secretions and improves remarkably the 
chances of the probiotics colonizing the intestinal mucosa (Sami et al., 2001).  When 
newborn ruminants were inoculated with a combination of pure probiotic cultures, 
colonization of the gut tissues was observed, and consequently the animals were better 
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endowed to resist infection by enterotoxigenic Escherichia coli (Cheng and Costerton, 
1988).  
Colonization is very important for the creation of balance of the intestinal microflora. 
Since bacteria adhere to mucus as well as to epithelial cells, it is believed that mucus has 
receptors mimicking the epithelial cells. Therefore, mucus can inhibit bacterial adhesion 
to epithelium. Although mucus serves as a protection to the intestinal mucosa from 
pathogenic microorganism infection, it also provides binding sites as well as nutrients for 
the bacteria. These factors may allow bacteria to multiply, which is a positive attribute 
towards probiotic colonization. Since mucus is continuously sloughed off into the 
intestinal lumen, and is replaced with new mucus secreted by goblet cells, bacteria 
inhabiting the mucus layer can only establish large populations when their multiplication 
exceeds the turnover and loss of the old mucus (Beachy, 1981).  
In a study of adhesion of Enterococcus faecum 18C23 to porcine intestinal mucus and 
its ability to inhibit adhesion of pathogenic Escherichia coli K88, Jin et al. (2000) 
reported that 90% of inhibition was achieved when 109 CFU/mL of E. faecum (18C23) 
culture was added at the same time with E. coli K88 to immobilized mucus. Such 
inhibition of adhesion of E. coli K88 by E. faecum (18C23) might occur through steric 
hindrance.  
Since adhesion to intestinal mucosa is paramount to establishment and colonization of 
host intestines by probiotics, Ouwehand et al., (2003) investigated the influence of 
disease on the capacity of bacterial mucosal adhesion. Using six strains of lactic acid 
bacteria, they observed that all strains adhered better to immobilized mucus than to whole 
intestinal tissue. However, L. rhamnosus and L. reuteri were found to show disease-
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specific adhesion to intestinal tissue. All strains, except L. rhamnosus, displayed disease-
specific adhesion to intestinal mucus. Their results strongly suggested that the strains, 
which bind better for a particular intestinal disease, could be selected for use as 
probiotics. 
 Asahara et al., (2001) investigated the antimicrobial activity of intraurethrally 
administered L. casei in a murine model of E. coli urinary tract infection (UTI). They 
observed that a single administration of L. casei Shirota at 108 CFU 24 hours before a 
three-week challenge with E. coli at 106 CFU in the urinary tract dramatically inhibited 
pathogen growth and inflammatory responses in the urinary tract, suggesting that L. casei 
Shirota may be used as a prophylactic agent for UTI. 
 
The role of probiotics in innate immunity 
In mediating the innate or non-specific immunity in host animals, several types of 
immune cells are recruited and stimulated. These cells include neutrophils, eosinophils, 
macrophages, epithelial cells, natural killer cells and M cells. These cells monitor sites of 
pathogen entry and mount nonspecific immune responses including phagocytosis and 
natural killing (Janeway et al., 1999). It is reported that innate immune responses in 
animals can be modulated by consumption of specific lactic acid bacteria (Perdigon et al., 
1995; Schiffrin et al., 1995). In a study conducted by Haller et al. (2000), human 
peripheral blood mononuclear cells (PBMCs) and purified lymphocyte subsets were 
capable of being stimulated by non-pathogenic gram-positive species of Lactobacillus. In 
vivo, interaction between nonpathogenic commensal bacteria and blood leukocytes may 
occur in definite compartments of the host’s mucosal immune system. They also reported 
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that increase in the number and immune function of lymphoid effector cells at the 
mucosal level is heavily dependent on the presence of gut microflora. Secretion of 
interferon-γ (INF-γ) from purified natural killer (NK) cells was significantly increased in 
the presence of macrophages primed with bacteria, suggesting that probiotic bacteria are 
important in the activation of NK cells by macrophages (Haller et al., 2000).   
It is well documented that there is recirculation of the mucosal immune system. Cells 
of the mucosal-associated lymphoid tissue (MALT) recirculate within the mucosal 
system. Given that there is evidence of translocation of nonpathogenic bacteria through 
the epithelial barrier via M-cell pockets, there is every chance that these bacteria interact 
with several types of immune cells, which are resident in M-cell pockets. Probiotic 
bacteria might exploit this fact to potentiate host immune function (Neutra, 1999).    
Phagocytosis is an important arm of the innate immune system and is among the first 
line of defense that animals employ in the event of infection by pathogenic 
microorganisms. Phagocytic cells are known to produce agents that are toxic to 
pathogens like reactive oxygen intermediates and lytic enzymes. They are involved in 
engulfing and destroying particulate antigens. Phagocytes may play an integral role in 
initiating inflammatory reactions. Salminen et al. (1998) reported that intestinal 
inflammation might be as a result of imbalance in the intestinal microflora. Gill et al., 
(2001) showed that both live and heat-killed preparations of L. rhamnosus HN001 had 
the capacity to enhance the phagocytic activity of blood and peritoneal leukocytes in 
mice after administration of 109 CFU of the microorganism daily. They observed that the 
enhancement of the phagocytic capacity was in a dose-dependent manner. However, they 
also demonstrated that mucosal antibody responses were enhanced by live but not killed 
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L. rhamnosus HN001. Their results suggest that while innate immunity is responsive to 
both killed forms of bacteria, only live forms are able to stimulate the gut mucosal 
immunity.  In an earlier study, Gill et al. (2000) demonstrated that feeding mice L. 
acidophilus or B. lactis resulted in a significant increase in the phagocytic activities of 
both PBMCs and peritoneal macrophages compared with control mice.  
An in vitro investigation conducted by Pinchuk et al. (2001) demonstrated that a 
probiotic strain, Bacillus subtilis 3, was able to secret antibiotics that inhibited growth of 
Helicobacter pylori. They showed that the anti-H. pylori activity in cell-free supernatants 
was heat stable and protease insensitive. Their result suggested that other probiotic 
preparations might exhibit similar activities against pathogenic microorganisms.  
 
The role of probiotics in acquired immunity 
Acquired or adaptive immunity is the response of antigen-specific lymphocytes to 
antigen and includes the development of immunological memory. Adaptive immune 
responses are generated by clonal selection of lymphocytes (Janeway et al., 1999). 
Acquired immunity involves lymphocytes with receptors for specific antigens and 
presentation of the antigens in the context of two different major histocompatibility 
complexes (MHC) by antigen presenting cells (APCs). As a result, subsets of helper T- 
cells (Th), the main effectors and regulators of cell-mediated immunity may be activated 
(Roitt et al., 1985). Upon activation by antigen or pathogen, T-cells are activated to 
synthesize and secrete a variety of cytokines that serve as growth, differentiation and 
activation factors for other immunocompetent cells. The types of cytokines produced 
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during infection are key factors in determining whether a humoral (antibody production) 
or a cellular immune response is potentiated in the host animal.  
Among the first proinflammatory cytokines expressed by host immune cells after 
pathogenic challenge are tumor necrosis factor-alpha (TNF-α), interleukin 1β (IL-1β), 
IL-6 and interferons (IFNs) (Tracey and Cerami, 1993). It is well documented that 
cytokines produced later during microbial infection will either influence the development 
of cell-mediated immune response associated with T-helper type 1 cells (Th1) or a 
humoral immune response that is associated with T-helper type 2 cells (Th2) (Abbas et 
al., 1996; Romagnani, 1996).  
Among major Th1 type cytokines are IL-12, IFN-γ and IL-18 of which IL-12 is 
known to stimulate IFN-γ production in both T and NK cells. It also promotes the 
development of naïve CD4+ T cells into Th1 type cells (Abbas et al., 1996; Trinchieri, 
1995). Phagocytic cells are known to enhance their IL-12 production after stimulation 
with IFN-γ, which has a down-regulatory effect on Th2 type cell proliferation and 
activation (Kohno and Kurimoto, 1998). Acting synergistically with IFN-α and IL-12, 
IL-18 is able to enhance IFN-γ expression in T cells (Sareneva et al., 1998). The 
development of naïve T cells to active Th2 type can be enhanced by IL-4 (Seder and 
Paul, 1994). IL-10, which is produced by both macrophages and lymphocytes, can 
enhance Th2 immune responses by inhibiting the production of TNF-α, IL-1β, IL-6, IFN-
γ and IL-12 (Abbas et al., 1996; D’Andrea et al., 1993; De Waal et al., 1991). 
Some have shown that LAB are able to induce the production of IFN-γ, IL-6, IL-10 
and TNF-α in human lymphocytes (Miettinen et al., 1996). Von der Wied et al. (2001) 
 15 
investigated the capacity of LAB to antagonize specific T-helper cell function in vitro 
and subsequent prevention of inflammatory intestinal immunopathologies. Their results 
showed that all LAB strains used were able to induce murine splenocytes to produce both 
IL-12 and IL-10. It is well known that IL-12 and IL-10 have the potential for induction 
and suppression of Th1 functions, respectively. Among all LAB strains used, L. 
paracasei NCC2461 induced the highest levels of both IL-10 and IL-12. They also 
showed that the proliferative activity of CD4+ T cells was strongly inhibited in a dose-
dependent manner by L. paracasei. In a further investigation, they demonstrated that this 
bacterium inhibited the secretion of Th1 and Th2 effector cytokines by CD4+ T cells, 
maintained the production of IL-10 and induced the secretion of transforming growth 
factor-β (TGF-β) by CD4+ T cells (Von Der Weid et al., 2001). 
In a study conducted by Pavan et al. (2003), they used a mouse model to evaluate the 
persistence, safety and immune modulation capacities of LAB. They demonstrated that 
TNF-α, IFN-γ, IL-10 and IL-4 were induced in healthy mice that received a single dose 
of L. plantarum NCIMB8826 or L. lactis for four consecutive days. When mRNA 
transcripts were assessed for these cytokines by semi-quantitative reverse transcriptase 
PCR, they found that there was higher expression of IFN-γ in the colon than in the ileum. 
However, the levels of IL-4 and IL-10 expression were significantly higher in the ileum 
than in the colon. Taken all together, these results suggested that there was a difference in 
Th1/Th2 balance between ileum and colon in mice. Since the bacterium persists in the 
mouse gut, it might be a suitable probiotic candidate for treatment of chronic 
inflammation.       
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Gill et al., (2000) observed that feeding healthy mice with 109 CFU of L. acidophilus, 
L. rhamnosus or B. lactis enhanced the proliferative responses of spleen cells to 
concanavalin A (Con A) and lipopolysacharide (LPS), which are T-and B-cell mitogens, 
respectively. The spleen cells from mice given these different bacteria expressed greater 
amounts of INF-γ after stimulation with Con A than cells from control mice. When they 
assayed the levels of antibody responses after either oral or systemic administration of 
antigen, they found the levels to be higher in mice given the bacteria than in control mice. 
Their results suggested the use of LAB as feed supplements in mice was able to enhance 
several factors of both humoral and cellular immune responses.  
Ibnou-Zekri et al., (2003) investigated the differential impacts of L. johnsonii and L. 
paracasei on the development of mucosal and systemic antibody responses in mice. 
Despite the fact that these two organisms had similar growth and adherence capacities to 
enterocytes in vitro, they showed marked differences in their patterns of colonization and 
translocation. They also promoted different immune responses at the mucosal and 
systemic levels in vivo. They demonstrated that of the strains tested, L. johnsonii 
colonized the intestines more efficiently than did L. paracasei in mice and that both 
strains activated mucosal B-cell responses evidenced by aggregation of cells of the 
Peyer’s Patches. They also showed that IgA secreting plasma cells were prevalent in 
lamina propria after association with either of the bacteria strains. Germ-free mice had 
either few or no IgA secreting cells even after association with either of the bacterial 
strains. They further showed that mice associated with L. johnsonii but not L. paracasei 
secreted increased amounts of Lactobacillus-specific IgA. 
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Waard et al. (2001) investigated the effects of orally administered viable L. casei 
Shirota on immune response indices of Wister and Brown Norway rats. They used the 
Trichinella spiralis host resistant model. In their study, two weeks before and after T. 
spiralis infection, rats were fed with 109 CFU of L. casei 5 days per week. They observed 
that T. spiralis-specific delayed-type hypersensitivity (DTH) responses were significantly 
augmented in mice fed L. casei than in control mice and significantly enhanced T. 
spiralis-specific antibody IgG2b in both types of rats. This type of DTH response is 
considered to be a manifestation of Th1 cell-mediated immunity.  
In an investigation on whether L. casei Shirota exhibited any activity against the 
influenza virus, Hori et al. (2001) observed that mice given the bacterium intranasally 
had greater expression of IL-12, IFN-γ, and TNF-α in their mediastinal lymph node cells. 
This high expression of cytokine helped in excluding the influenza virus. They observed 
that viral titers in the nasal washes of mice given the bacterium before infection with the 
pathogenic virus were significantly lower than in those not inoculated with the bacterium. 
They also observed that the survival rate of the mice inoculated with the bacterium was 
higher than that of the mice not inoculated, after both groups were challenged with the 
virulent virus. They concluded that because the viral titers were decreased in mice 
inoculated with L. casei Shirota to about a tenth of the viral titers found in the control 
group, administration of the bacterium enhanced cellular immune response in upper 
respiratory tract of mice and conferred protection to them against the influenza virus 
infection (Hori et al., 2001). Yasui et al., (1999) reported that another probiotic 
bacterium, B. breve YIT 4064, was able to potentiate humoral immune response and that 
oral administration of this strain was able to augment production of antigen-specific 
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immunoglobulin G in serum and conferred protection against influenza virus infection in 
mice.  
Matsuguchi et al., (2003) investigated the stimulatory effects of Lactobacillus species 
on mouse immune cells. In their investigation, six heat-killed cultures were used, 
including L. fermentum, L. rhamnosus, L. casei, L. plantarum, L. acidophilus and L. 
reuteri. They observed that splenic mononuclear cells from BALB/c mice were induced 
by all six strains to produce TNF-α in varying amounts. They also observed that the 
protoplast fractions of Lactobacillus had the highest activity for TNF-α induction and 
NF-κB activation in a macrophage cell line RAW264.7. In a further experiment they 
observed that Toll-like receptor-2 (TLR2) but not TLR4 was essential for induction of 
TNF-α  by Lactobacillus lipoteichoic acid (LTA). They also demonstrated that TLR2 
mediated the activation of NF-κB by Lactobacillus LTA and that TLR2 was essential for 
cell response to Lactobacillus strains but not TLR4 including eliciting of 
proinflammatory reactions.  
 
Selection of probiotic strains 
Some of the most important factors to consider when selecting a probiotic strain are 
to screen their capabilities for mucosal adhesion, mucosal penetration, inhibition of 
pathogen growth, resistance to bile, resistance to peristaltic gut movements, and tolerance 
to low pH (Sami et al.,2001). It is established that interaction with mucus is among the 
initial steps in adhesion of bacteria to the intestinal mucosa and other surfaces. This 
interaction may promote competitive exclusion by probiotic microorganisms by 
competition for nutrients, blocking adhesion receptors and production of antimicrobial 
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substances. The overall result is blockage of entry sites for host pathogens (Sami et al., 
2001). The choice probiotic, therefore, should be one that is able to multiply fast and out-
compete some of the hosts’ resident microflora. 
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Chapter III 
Modulation of Immune Responses in calves by Lactic Acid Bacteria (Probiotics) 
 
Abstract 
 Some probiotic bacteria can favorably alter the balance of intestinal microfloral, 
inhibit the growth of pathogenic bacteria, promote nutrient digestion, increase resistance 
to infection and boost immune function. Two experiments were conducted to investigate 
the immune modulatory effects of feeding 3 to 4 month-old healthy Holstein female 
calves with 109 colony-forming units (CFU).calf-1.d-1 of Lactobacillus acidophilus 381-
IL-28. In the first experiment, a total of eight animals were divided into two groups with 
four calves having their diets supplemented with the bacteria, while the other four served 
as controls. On days 0, 2, 4, 7, 14, and 21, animal weights were recorded, and fecal 
samples and peripheral venous blood were collected from each calf. In the second 
experiment, six calves were supplemented with probiotics in their diets, while the other 
five served as controls. On days 0, 7, 14, 21, 28, and 35, periperal venous blood was 
obtained from the animals. Fecal temperatures and fecal pH were recorded and animals 
were weighed. In both experiments, differential white blood cell counts were determined. 
White blood cells were isolated and their phagocytosis capacity was determined by flow 
cytometry. Total RNA was also extracted from white blood cells, and used to measure the 
cytokine gene expression by semi-quantitative reverse transcriptase-polymerase chain 
reaction (RT-PCR). In addition, serum IgA levels were measured by enzyme-linked 
immunosorbent assay (ELISA). The results indicated that there was no statistical 
difference between probiotic treated and control animals in weight gain, fecal 
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temperature, fecal pH, phagocytosis capacity, differential white blood cell counts, and 
cytokine expression levels in white blood cells throughout different sampling times in 
either experiment. There also were no significant difference between serum IgA of the 
two groups of animals in either experiment. Taken together, these results suggested that 
feeding healthy Holstein calves with 109 CFU.calf-1.d-1 of L. acidophilus was not 
sufficient to augment either innate or adaptive immune responses. A different dose or 
strain of probiotics may be needed in the future to evaluate their effect on immunity of 
Holstein calves. 
 
Introduction 
 For the host to be protected against infection, it must have a normal intestinal 
microflora, which serves as an extremely important barrier against pathogenic 
microorganisms (Wells et al., 1982). Oral consumption of health-promoting lactic acid 
producing bacteria or probiotics has been associated with prevention, alleviation or cure 
of diverse intestinal disorders (Alander et al., 1999). It is generally accepted that use of a 
probiotic, defined by Fuller as “a live microbial feed supplement which beneficially 
affects the host animal by improving its microbial balance” (Fuller, 1989), is an 
interesting approach for prevention and treatment of some infectious intestinal diseases 
(Banasaz et al., 2002). In recent years, data based on clinical studies indicating health-
promoting properties of several probiotic strains have started to accumulate (Lee and 
Salminen, 1995). Although many mechanisms have been proposed by which probiotics 
promote intestinal health and overall well-being of the host animal, one of the most 
important mechanisms is modulating host immune function (Isolauri et al., 2001).  
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 The mammalian immune system is capable of mounting both the innate and adaptive 
immune responses when challenged by a pathogenic microorganism. The gastrointestinal 
tract of mammals is resident to various immune cells including epithelial cells, 
macrophages, lymphocytes, neutrophils, natural killer cells and dendritic cells. All these 
cells are aggregated in Peyer’s Patches, lamina propria and intraepithelial regions 
(Janeway, 1999). These immune cells are quickly activated upon infection leading to 
enhanced phagocytosis and production of various humoral mediators, which collectively 
provide immediate protection for the host or initiate the development of specific immune 
responses (Zhang and Ghosh, 2001). Some of the humoral mediators produced upon 
infection include cytokines, which will promote a Th1 or a Th2 immune response 
(Infante-Duarte and Kamradt, 1999). Probiotic bacteria have been shown to affect innate, 
humoral and cellular arms of the immune system. Oral administration of Lactobacilli 
resulted in enhanced phagocytosis and natural killer activities as well as elevated 
production of IgA and decreased IgE production in both humans and animals (Isolauri et 
al., 2001). 
Gastrointestinal diseases continue to cause significant economic losses in the bovine 
industry. Diarrhea is one of the most common causes of neonatal mortality in cattle. Poor 
growth performance, which normally accompanies diarrhea and subsequent low feed 
efficiency, are areas of major concern to the bovine industry. Most of the diarrhea is 
caused by enteric pathogens such as Escherichia  coli and Salmonella (Levy, 2000). In 
the recent past, there has been an abated emergence of antibiotic-resistant bacteria, which 
is not only posing serious concerns to public and health specialists, but also to food 
animal producers (Teuber, 2001). Consumers have continued to criticize the practice of 
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using massive antibiotics in animal feeds as growth promoters and means of disease 
control (Threlfall et al., 2000). The unchecked use of antibiotics could increase the 
prevalence of antibiotic-resistant bacteria in the environment, and there is a fear of 
contaminating animal food products with drug-resistant pathogens. The use of probiotics 
in disease management and treatment could serve as an alternative to the use of 
antibiotics. Evidence continues to accumulate about the beneficial effects of probiotics on 
the prevention and treatment of gastroenteric diseases (Marteau et al., 2001). 
     In the present study, two animal experiments were conducted to investigate the effects 
of lactic acid-producing bacteria, L. acidophilus, on local and systemic immune responses 
in cattle. We hypothesized that L. acidophilus is capable of influencing both mucosal and 
systemic immune responses by modulating differential white blood cell counts and 
phagocytic activity of white blood cells as well as the production of immunoglobulins, 
cytokines and disease resistance molecules in Holstein calves.  
 
Material and Methods 
 
Lactobacillus acidophilus preparation 
The probiotic used in this study was L. acidophilus 381-IL-28, which was kindly 
provided by Culture systems, Inc. (Mishawaka, IN) in a lyophilized form with lactose as 
a carrier. Each bag contained enough bacteria to feed 4-6 calves with 1 x 109 CFU.calf-
1
.d-1.  
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Experimental design 
Two independent animal trials were conducted in accordance with and approved by 
the Oklahoma State Institutional Animal Care and Use Committee. In the first animal 
trial, eight healthy, 3-month-old, female Holstein calves were (initial BW = 97 ± 22 Kg) 
divided into two groups based on their weight and ancestry and housed in the Nutrition 
and Physiology Research Center at Oklahoma State University. The calves were fed 
twice daily with 4 kg/d of a standard mixed grain ration without antibiotics, but 
supplemented with rumensin, an ionophore with bacteriostatic effects. The animals were 
allowed free access to water and alfalfa hay cubes. After two weeks of acclimatization, 1 
x 109 CFU.calf-1.d-1 of L. acidophilus 381-IL-28 were added to the mixed grain ration and 
fed individually to 4 calves. The other 4 calves did not receive any Lactobacillus but 
were fed the mixed grain with the addition of an amount of lactose comparable to that 
used as carrier for the dried cells of L. acidophilus; these animals served as the control 
group. The trial was conducted for three weeks. Samples from the animals were collected 
on d 0, 2, 4, 7, 14, and 21 following acclimatization.  
The second trial involved a total of 11 healthy, 3-month old female Holstein calves 
(initial BW = 185 ± 30 Kg). They were divided into two groups based on their weights 
and ancestry and housed in the Nutrition and Physiology Research Center. The calves 
were fed twice daily with 4 kg/day of mixed grain ration without both rumensin and 
antibiotics. After three weeks of acclimatization, 1 x 109 CFU.calf-1.d-1 of L. acidophilus 
381-IL-28 were added to the mixed grain ration and fed individually to six calves. The 
other five calves did not receive any Lactobacillus but were fed mixed grain with the 
addition of the same amount of lactose and these animals served as the control group. On 
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d 0, 7, 14, 21, 28 and 35, the calves were weighed and their weights recorded. Their 
rectal temperatures, taken with a clinical thermometer, were recorded. At the same time, 
10 mL of whole blood and 40 mL of uncoagulated blood were collected from the jugular 
vein using vacuum tubes. Heparin was used as anticoagulant. These blood collection 
procedures were done on the calves secured in a chute. The sampling procedures were 
carried out in the mornings before the animals were fed. 
 
Isolation of white blood cells by hypotonic lysis of red blood cells 
White blood cells were isolated from uncoagulated blood by hypotonic lysis as 
described previously (Zhang et al., 1997; Zhang et al., 1999). Basically, hypotonic lysis 
of erythrocytes was done by addition of 0.2% sterile NaCl to the blood with gentle 
mixing for about 30 to 40 seconds followed by addition of an equal amount of 1.6% 
NaCl. The mixture was centrifuged (500 x g) and cell pellet was saved. Two or three 
rounds of lysis and centrifugation were carried out until a white pellet of cells was 
obtained. The cell pellet (i.e., white blood cells) was then resuspended in 4 mL of cell 
culture medium, RPMI1640, counted with a hemocytometer, and maintained on ice. 
 
Phagocytic activity of the white blood cells 
Phagocytosis assays were conducted in accordance with the Vibrant Phagocytosis 
Assay Kit (V-6694) from Molecular Probes, Inc. (Eugene, OR). In general, 1 mL of 
isolated white blood cells (106 cells/mL) from each calf were mixed with 2 µL of 
fluorescein-labeled E. coli (K-12 strain) and incubated with gentle rocking on a platform 
(Midwest Scientific, Model: Reliable Scientific, St. Louis, MO) at 37oC for 30 minutes. 
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After incubation, the cells were centrifuged at 500 x g for 5 minutes at 4oC and the cell 
pellet was washed twice with 2 mL of cold PBS. The cells were then fixed in 1 mL of 2% 
formaldehyde on ice for 10 minutes. Trypan blue (50 µL of 4 mg/L) was added to each 
tube and mixed by vortexing and then analyzed by a FACS flow cytometer (Becton 
Dickson, Model: FACS caliber, Franklin Lakes, NJ). The negative controls were viable 
cells resuspended in RPMI1640 without the addition of fluorescein-labeled E. coli.  Each 
experimental sample was done in triplicate. 
 
Differential white blood cell count 
All procedures used during the differential white blood cell counts were conducted in 
accordance with PROTOCOLTM Hema–Qick III Kit for Wrights-Giemsa staining from 
Fisher Diagnostics Inc. (Middletown, VA). A drop of blood without anticoagulant was 
used to make the blood smear. The smear was let to dry at room temperature and later 
stained with Hema III stain kit. The slides were then observed under a light microscope 
using the oil immersion objective. The first 100 cells were identified and number of each 
cell type recorded.  
 
Measurement of gene expression levels by reverse transcriptase-PCR (RT-PCR) 
Total RNA was isolated from about 107 cells using the Trizol Reagent (Invitrogen, 
Life Technologies, San Diego, CA) and subsequent RT-PCR was carried out essentially 
as described previously (Zhang et al., 1997; Zhang et al., 1999). The first-strand cDNA 
synthesis were conducted with ImProm-II Reverse Transcriptase (Promega, Madison, 
WI) with 4 µg of total RNA. The PCR was done in a total of 20 µL with 0.5 µL of first-
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strand cDNA in the presence of specific primers for either house-keeping gene (β-actin) 
or genes of interest (Table 1). The PCR was performed by using the following program: 
94oC for 2 minutes, and then different cycles of 94oC for 30 seconds, 55oC for 30 
seconds, and 72oC for 1 minute.  
   Table 1. A list of gene-specific primers used for cytokine gene RT-PCR 
IL-Iβ   
        Sense primer: GTGTTCTGCATGGAGCTTTGTG 
       Antisense primer: GCTTTCT (/C) TTAGGGAGAGAGG 
       PCR product size: 349 bp 
IL-8 
       Sense primer: CTCTCTTGGCAGC (/T) TTTCCTG 
      Antisense primer: TCTGCACCCACTTTTCCTTGG 
      PCR product size: 237 bp 
IL-10 
      Sense primer: TTACCTGGGTTGCCAAGCCT 
      Antisense primer: TTGTAGACACCCCTCTCTTGG 
      PCR product size: 240 bp 
IL-12p40 
      Sense primer: TCAGGGACATCATCAAACCAG 
      Antisense primer: GACACAGATGCCCATTCACTC 
      PCR product size: 286 bp 
IL-18 
      Sense primer: CCTGGAATCA (/G) GATC (/T) ACTTTGG 
      Antisense primer: TACACTGCACAGAGATGGTTAC 
      PCR product size: 218 bp 
IFN-γ 
      Sense primer: AACCAGGC (/T) CATTCAAAGGAGC 
      Antisense primer: GAAATAGTCACAGGATACAGG 
      PCR product size: 437 bp 
iNOS 
      Sense primer: ACTTGGCTAACGGAACTGGAC 
      Antisense primer: TTCTGGTGAAGCGTGTCTTG 
      PCR product size: 259 bp 
TGF-β 
      Sense primer: CAACTACTGCTTCAGCTCCAC 
      Antisense primer: CGCACGATCATGTTGGACA 
      PCR product size: 309 bp 
NRAMP1 
      Sense primer: ACAGCAGCCTCCACGACTAC 
      Antisense primer: TTCAGGAAGCCCTCCATCACA 
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      PCR product size: 205 bp 
 
ELISA analysis of IgA and levels in serum  
The serum samples were prepared from peripheral venous blood collected in 10 mL 
vacuum tubes without anticoagulant. The blood was let to coagulate at 4 0C and then 
centrifuged at 500g. The supernatant (serum) was aspirated and saved at –20 0C for future 
IgA assay. ELISA assays of for IgA levels in serum were performed with ELISA Kits 
from Bethyl Laboratories (Montgomery, TX) according to the manufacturer’s 
instructions. Briefly, 1 µL capture antibody was diluted to 100 µL in the coating buffer 
(0.05 M Carbonate-Bicarbonate, pH 9.6), added in 96 well microplates, and incubated for 
60 minutes at room temperature. After incubation, the excess capture antibody was 
aspirated from each well and the wells washed with wash solution (50 mM Tris, 0.14 M 
NaCl, 0.05% Tween 20, pH 8.0) three times. The coated plate was then blocked with 200 
µL of blocking solution (50 mM Tris, 0.14 M NaCl, 0.05% Tween 20, pH 8.0) for 30 
minutes at room temperature followed by washing three times with wash solution. 
Bovine serum albumin (BSA) was added to the blocking solution.Serum samples were 
thawed on ice and diluted to 1:10,000. Standards were diluted in the same sample diluent 
according to the instruction. One hundred microliters of the samples or standards (from 
the kit) were added to the assigned wells. Standards, samples, and blanks were analyzed 
in duplicate. The plates were then incubated for 60 minutes at room temperature. After 
incubation, the samples and standards were removed by aspiration and the wells washed 
five times with wash buffer.  
Horseradish peroxidase (HRP) conjugated capture antibody was diluted in the wash 
buffer to 1:35,000. To each well, 100 µL of the diluted HRP conjugate was added and 
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then the plate incubated for 60 minutes. The plates were washed five times with wash 
solution. The color was developed by adding 100 µL/well of the substrate solution, 3,3” 
5,5” tetramethylbenzidine (TMB), followed by incubation at room temperature for 15 
minutes, after which the reaction was stopped by the addition of 100 µL of 2 M sulphuric 
acid. The color was read at 450 nm using a microtiter plate reader (Molecular Devices, 
Sunnyvale, CA). The averages of the duplicate readings from each standard, control and 
sample were calculated. The Blank reading was subtracted from each of the averages. A 
standard curve was then generated for standards. The IgA concentration of each sample 
was then extrapolated from the standard curve.  
 
Statistical Analyses 
Proc Mixed analysis of Statistical Analysis System (SAS Institute, Cary, NC) was used. 
Experiments 1 and 2 were analyzed separately. Animal served as the experimental unit. 
Data are presented as Least squares (LS) means ± standard error. All data were analyzed 
as a completely random design with repeated measures over days. The model included 
fixed effects of treatment, day and treatment x day. Differences were considered 
statistically significant if P< 0.05.
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Results and Discussion 
 
Effect of probiotics on growth performance, body temperature and fecal pH 
Results from Exp. 1 and 2 indicated that supplementation of calf diets with probiotics 
did not improve the BW gain (P = 0.97 and 0.08 respectively; Fig. 1 and 2; Table 2). The 
increase in body weight was due to normal growth of the healthy calves as a result of 
normal feeding. Increasing growth rates across days were reflected in an obvious day 
effect in both trials (P <0.001 for both). There was no day x treatment interaction when 
body weight gain was analyzed (P = 0.73 and 0.36 for Exp. 1 and 2, respectively). 
However, there was a significant difference in average weight gain observed between 
treatment and control animals in Exp. 2 (P = 0.008) on d 35, which was probably caused 
by a small number of animals used. 
 The fecal pH analysis showed no significant day, treatment, nor day x treatment 
effects (P = 0.83, 0.19 and 0.58, respectively) in Exp. 1 (Fig. 3 and Table 3). When 
animal rectal temperatures were analyzed, no significant treatment effect was observed in 
either trial (P = 0.77 and 0.69 for Exp. 1 and 2, respectively; Table 3), but there was a 
significant day effect (P = 0.02 and P <0.001 for Exp. 1 and 2, respectively) (Fig. 4 and 
5). The day effect may be attributed to changes in environmental temperature since the 
trials were done in summer and environmental temperatures fluctuated, particularly in the 
second animal trial. There was no day x treatment effect for rectal temperature (P = 0.98 
and P = 0.57 for Exp. 1 and 2, respectively). 
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Effect of probiotic on serum IgA concentrations 
 Probiotic treatment has been shown to enhance the number of IgA-producing plasma 
cells in a dose-dependent manner (Perdigon et al., 1995). In the present experiments, 
serum IgA concentrations were measured. The results showed no significant differences 
in IgA levels between probiotic treated and control animals (P = 0.61 and 0.30 for Exp. 1 
and 2, respectively; Fig. 6 and 7; Table 4). The failure in enhancing secretion of IgA in 
the serum implied that more than 109 CFU.calf-1.d-1 might be needed to exert beneficial 
effects in Holstein calves. Alternatively, longer duration of administration or different 
strains of probiotics might be needed. 
 
Effect of probiotic on regulation of host immune responsive genes 
 Although several studies have shown that cytokine production by cells of the immune 
system can be altered by probiotic use (Tejada-Simon et al., 1999), our results showed 
that most of the proinflammatory cytokine genes were not upregulated in probiotic-
treated animals (data not shown). For example, constant expressions of IL-1β and IL-8 
were observed on Days 7 and 35 in both groups of animals (Fig. 10).  In fact, this 
phenomenon was seen across all sampling days, consistent with the findings of Tejada-
Simon et al. (1999), who reported no effect of repeated oral exposure to viable or killed 
L. acidophilus on basal cytokine mRNA expression in Peyer’s Patches, spleen or lymph 
nodes of mice after 14-day exposure. In contrast, Miettinen et al. (1996) showed a strong 
induction of IL-1β and IL-18 protein secretion when human peripheral mononuclear cells 
were stimulated with non-pathogenic strains of Lactobacillus. 
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Effect of probiotic on differential counts and phagocytic activity of white blood cells 
(WBC) 
Leukocytes in cattle blood primarily consist of neutrophils, lymphocytes and 
monocytes. Differential white blood cell count is an important criterion in detection of 
infection with both viruses and bacteria. Our results indicated that feeding probiotics did 
not cause a statistical difference in the percentage of lymphocytes (Fig. 11), monocytes 
(Fig. 12), or neutrophils (Fig. 13), on any sampling day in the first experiment. Consistent 
with these results, there was no difference in differential WBC counts for lymphocytes 
except on d 7 (P = 0.037) in Exp. 2 (Fig. 14).  Similarly no statistical difference was 
observed in monocyte counts in Exp. 2 (Fig. 15). However, the percentage of neutrophils 
in control animals in Exp. 2 was greater (P = 0.005) than in animals whose diets had been 
supplemented with probiotics (Fig. 16; Table 5). The difference in percentage of 
neutrophils between the two groups of animals was significant on d 21 (P = 0.0134). 
Since the animals used in this experiment were healthy and the probiotic used, L. 
acidophilus, is non-pathogenic, a decrease in the percentage of neutrophil counts most 
likely was due to a small sample size (a total of eleven animals were used in the second 
experiment).  
Furthermore, the phagocytic activity of white blood cells was also measured in both 
experiments. The results indicated that no difference in phagocytic capacity was observed 
between control animals and animals treated with probiotics (P = 0.62 and P = 0.53 in 
Exp. 1 and Exp. 2, respectively; Fig. 17 and Fig. 18; Table 6). Therefore, it can be 
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concluded that supplementation with the probiotic did not enhance the phagocytic 
capacity of blood leukocytes.  
Collectively, these results revealed no beneficial effect of feeding 109 colony-forming 
units (CFU).calf-1.d-1 of Lactobacillus acidophilus 381-IL-28 to 3 to 4-month-old 
Holstein calves on both innate and adaptive immune responses. However, large-scale 
experiments involving the use of a larger number of animals need to be performed to 
confirm this conclusion. Moreover, a different dose or strain of probiotic also warrants 
further investigation. 
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Fig. 1. Effect of probiotic on weight gain of calves in Exp.1. There was a significant day 
effect (P < 0.0001) and no significant treatment (P = 0.97) nor day x treatment (P = 0.73) 
effects on weekly weight-gain of the calves. SEM = 2.12 
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Fig. 2. Effect of probiotics on average calf weekly weight gain in Exp. 2 showing 
tendency towards a significant treatment effect (P = 0.08) with control animals having a 
higher weekly weight gain in general. There was a significant difference in average 
weight gain observed on day 35 between the two groups of animals (P = 0.008). SEM = 
2.4 
 
 
P = 0.008 
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Table 2.  Effect of probiotics on growth performance 
Experiment 1 
Item Control Probiotic SEM P-value 
n 20 20   
Weight gain 
(Kg) 
10.36 10.31 2.12 0.97 
Experiment 2 
Item Control Probiotic SEM P-value 
n 30 36   
Weight gain 
(Kg) 
26.22 23.1 2.4 0.08 
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Fig. 3. Effect of probiotics on fecal pH in Exp.1. There was no significant day (P = 0.83), 
treatment (P = 0.19) nor day x treatment (P = 0.58) effects on fecal pH. SEM = 0.13 
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Fig. 4. Effect of probiotics on calf rectal temperatures in Exp. 1. No significant treatment 
nor day x treatment effects with P values of 0.77 and 0.98, respectively. There was a 
significant day effect (P = 0.02) due to fluctuation daily environmental temperature 
during the experimental period. SEM = 0.24 
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Fig. 5. Effect of probiotics on calf weekly rectal temperatures in Exp. 2. No significant 
treatment or day x treatment effects with P values of 0.69 and 0.57, respectively. There 
was a significant day effect (P < 0.001). Daily environmental temperature varied during 
the experimental period. SEM = 0.85 
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Table 3. Effect of probiotics on fecal pH and rectal temperature 
Experiment 1 
Item Control Probiotic SEM P-Value 
n 16 16   
Fecal pH 6.67 6.42 0.13 0.19 
Rectal temp 0F 103.6 103.7 0.24 0.78 
Experiment 2 
Item Control Probiotic SEM P-Value 
n 30 36   
Rectal temp 0F 102.16 102.21 0.85 0.69 
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Fig. 6. Effect of probiotics on serum IgA levels in Exp. 1. There was no day (P = 0.87), 
treatment (P = 0.61) nor day x treatment (P = 0.27) effects on IgA levels. SEM = 1.0 x 
105 
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Fig. 7. Effect of probiotics on serum IgA levels in Exp. 2. No significant day (P = 0.47), 
treatment (P = 0.30) nor day x treatment (P = 0.80) effects were observed between the 
probiotic-treated and control animals on IgA levels.  SEM = 8.7 x 104 
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Table 4. Effect of probiotics on serum concentrations of IgA and IgG 
Experiment 1 
Item Control Probiotic SEM P-Value 
n 12 12   
IgA (ng/mL) 4.3 x 105 3.4 x 105 1.0 x 105 0.60 
Experiment 2 
Item Control Probiotic SEM P-value 
n 30 36   
IgA (ng/mL) 6.6 x 105 5.3 x 105 8.7 x 104 0.30 
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Fig. 8. Effect of probiotic on cytokine gene expression on day 7 (A) and day 35 (B) in 
Exp. 2. There was no significant difference in cytokine gene expression levels between 
probiotic-treated and control animals. The cytokine genes, IL-1β and IL-18 were 
amplified from cDNAs prepared from total RNA isolated from white blood cells prepared 
from blood samples collected on days 7 and 35, respectively.  
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Fig. 9. Effect of probiotics on lymphocytes counts in Exp.1. A significant day (P = 0.04) 
effect was observed with no significant treatment (P = 0.88) nor day x treatment (P = 
0.96) effects on lymphocyte counts. SEM = 1.91 
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Fig. 10. Effect of probiotic on monocyte counts in Exp. 1. No significant day (P = 0.37), 
treatment (P = 0.43) nor day x treatment (P = 0.56) effects were observed on monocyte 
counts between probiotic and control animals. SEM = 1.3 
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Fig. 11. Effect of probiotic on neutrophils counts in Exp.1. A significant day effect (P = 
0.0481) was observed with no significant treatment (P = 0.99) nor day x treatment (P = 
0.61) effects on neutrophil counts between probiotic-treated and control animals. SEM = 
1.99 
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Fig. 12. Effect of probiotic on lymphocyte counts showing significant day (P = 0.009) 
and treatment (P = 0.024) effects in Exp. 2. The difference in lymphocyte counts between 
probiotic-treated and control animals was significant on day 7 (P = 0.037).  There was no 
significant day x treatment effect (P= 0.67). SEM = 0.93 
P = 0.037 
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Fig. 13. Effect of probiotic on monocyte counts in Exp. 2; no significant day (P = 0.32), 
treatment (P = 0.1905) nor day x treatment (P = 0.98) effects were observed. SEM = 1.33 
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Fig. 14. Effect of probiotic on neutrophil counts in Exp. 2. There was a significant 
treatment effect (P = 0.052) with control animals showing generally higher neutrophil 
count. The difference was most significant on day 21 (P = 0.013). SEM = 1.21 
P = 0.013 
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Table 5. Effect of probiotics on differential white blood cell count 
 
Experiment 1 
Item Control Probiotic SEM P-value 
n 24 24   
% Neutrophils 33.25 33.20 1.99 0.98 
% Lymphocytes 35.62 36.04 1.91 0.88 
% Monocytes 31.25 30.25 1.30 0.43 
Experiment 2 
Item Control Probiotic SEM P-value 
n 30 36   
% Neutrophils 30.70 25.00 1.21 0.005 
% Lymphocytes 37.56 40.80 0.93 0.02 
% Monocytes 31.96 34.11 1.33 0.19 
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Fig. 15. Effect of probiotic on the phagocytic activity of white blood cells in Exp. 1. 
There was a significant day (P < 0.0001) with no significant treatment (P = 0.62) nor day 
x treatment (P = 0.82) effects observed. Therefore, there was no significant difference in 
phagocytosis capacity between immune cells from probiotic treated and control animals. 
SEM = 2.5 
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Fig. 16.  Effect of probiotic on the phagocytosis capacity of isolated white blood cells 
from both probiotic treated and control animals in Exp. 2. The results showed neither 
significant treatment (P = 0.53) nor day x treatment (P = 0.63) effects. SEM = 0.69 
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Table 6.  Effect of probiotics on phagocytosis of total white blood cells 
Experiment 1 
Item Control Probiotic SEM P-value 
n 20 20   
% Phagocytosis 28.8 30.7 2.5 0.61 
Experiment 2 
Item Control Probiotic SEM P-value 
n 30 36   
% Phagocytosis 14.94 14.31 0.69 0.53 
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Appendix 
Raw data 
Exp. 1. 
Animal 
ID 
TRT 
 
Day 
 
Phagoc 
(%) 
IgA 
(ng/ml) 
Neu 
(%) 
Lymp 
(%) 
Mono 
(%) 
Wt Gain 
(Kg) 
Temp 
(oF) 
pH 
 
306 PRO 0 12.19 302508 30 38 32   6.55 
308 CON 0 9.63 896653 24 41 35   7.13 
311 PRO 0 23.68 241466 24 31 43   6.33 
307 PRO 0 10.82 1151000 27 47 26   6.13 
309 CON 0 9.6 234836 36 42 22   6.5 
310 CON 0 17 421333 21 53 26   7.13 
303 PRO 0 8.7 75197 37 40 23   5.65 
305 CON 0 5.93 265532 39 31 30   5.87 
           
306 PRO 2 23.66  42 38 20 5.9  6.37 
308 CON 2 38.4  27 45 28 7.2  6.62 
311 PRO 2 33.77  22 49 29 8.2  7.07 
307 PRO 2 27.78  26 48 26 1.4  6.67 
309 CON 2 34.92  23 50 28 4.5  6.6 
310 CON 2 43.1  29 33 38 4.0  6.99 
303 PRO 2 54.77  37 33 30 3.6  5.36 
305 CON 2 27.45  34 39 27 3.6  7.45 
           
306 PRO 4 54.72  38 22 30 5.9 103.8 6.59 
308 CON 4 49.08  42 33 25 6.8 103.2 6.2 
311 PRO 4 44.27  41 37 22 9.0 103.4 5.74 
307 PRO 4 32.08  29 42 29 5 103.2 6.79 
309 CON 4 33.19  28 37 35 6.8 102.5 6.79 
310 CON 4 49.26  35 23 42 7.2 103.6 6.76 
303 PRO 4 51.81  36 34 30 8.6 103.8 6.69 
305 CON 4 33.83  37 37 30 10 104.2 6.37 
           
306 PRO 7 31.3 348166 34 42 24 10.4 103.6 5.58 
308 CON 7 38.99 242549 33 42 25 8.6 103.4 6.49 
311 PRO 7 30.48 170421 35 37 28 8.6 103.8 7.21 
307 PRO 7 23.54 1192000 26 43 31 12.7 103.2 6.81 
309 CON 7 19.16 188122 31 35 34 4.5 102.8 6.85 
310 CON 7 29.16 311233 29 32 39 10.9 103.2 7.2 
303 PRO 7 29.15 75179 34 29 37 12.7 104 7.2 
305 CON 7 23.54 265532 38 30 32 11.8 104.8 5.74 
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306 PRO 14  156441 37 27 36 4.5 105  
308 CON 14  1235000 22 45 43 4.5 104.1  
311 PRO 14  265537 36 29 35 5.4 103.2  
307 PRO 14  187114 28 46 26 8.2 104.3  
309 CON 14  302544 43 19 38 1.4 103.1  
310 CON 14  453250 25 41 34 9.0 103.4  
303 PRO 14  72058 35 29 36 7.2 104.2  
305 CON 14  353603 36 31 33 9.5 105.6  
           
306 PRO 21   38 30 32 23.6 103.8  
308 CON 21   36 34 30 24 104.1  
311 PRO 21   30 28 42 12.3 103  
307 PRO 21   26 41 33 22.2 104  
309 CON 21   48 25 27 23.6 103  
310 CON 21   38 23 39 24.5 103.1  
303 PRO 21   49 25 26 30.4 102.9  
305 CON 21   44 34 22 24.0 103.5  
 
Exp. 2 
Animal 
ID 
TRT 
 
Day 
 
Phagoc 
(%) 
IgA 
(ng/ml) 
Neu 
(%) 
Lymp 
(%) 
Mono 
(%) 
Wt Gain 
(Kg) 
Temp 
(oF) 
291 PRO 0 18.16 607326 40 35 25  102.2 
292 CON 0 14.29 575133 22 48 30  103.1 
293 PRO 0 14.79 1183570 25 42 33  103.4 
295 PRO 0 14.14 886072 26 45 29  102.7 
296 CON 0 15.5 776955 21 52 27  105.3 
297 PRO 0 19.05 326263 28 46 26  103.3 
298 CON 0 19.89 581275 18 36 46  102.8 
300 PRO 0 15.55 363652 20 48 32  103.1 
301 CON 0 15.31 311331 26 45 29  103.4 
302 PRO 0 16.03 780788 20 38 42  102.4 
304 CON 0 14.29 1433000 39 37 24  102.7 
291 CON 7 13.19 648388 32 38 30 13.2 101.8 
292 PRO 7 14.53 468272 19 38 43 10.9 102.1 
293 CON 7 11.55 659191 27 43 30 11.3 102.0 
295 PRO 7 9.95 1021098 24 31 45 2.3 102.2 
296 PRO 7 10.47 522456 27 31 42 5.9 102.3 
297 CON 7 18.61 284980 24 47 29 8.6 102.7 
298 PRO 7 12.73 410448 24 40 36 6.8 101.9 
300 CON 7 13.91 363440 17 44 39 5.4 101.4 
301 PRO 7 11.11 632086 30 40 30 3.6 101.4 
302 CON 7 10.69 527553 25 45 30 9.0 102.1 
304 PRO 7 10.59 803512 31 25 44 14.5 101.9 
291 PRO 14 14.95 367404 29 33 38 20.4 101.8 
292 CON 14 10.04 437055 28 41 31 19.0 101.6 
293 PRO 14 10.85 858738 25 38 37 17.3 102.1 
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295 PRO 14 4.55 418286 33 28 39 16.8 102.2 
296 CON 14 9.835 463843 31 42 27 21.8 101.5 
297 PRO 14 10.98 287036 34 37 29 16.4 101.6 
298 CON 14 13.97 333732 31 39 30 17.7 102 
300 PRO 14 11.4 356144 26 38 36 14.1 101.8 
301 CON 14 8.42 734798 26 30 44 16.8 101.9 
302 PRO 14 16.93 486797 14 38 48 19.1 101.7 
304 CON 14 11.85 1756000 40 35 25 24.1 102 
291 PRO 21 16.72 420018 26 42 32 28.2 102 
292 CON 21 17.68 421914 22 49 29 25.4 102 
293 PRO 21 11.88 605198 28 40 32 17.3 102.2 
295 PRO 21 6.815 483226 32 36 32 29.5 102.2 
296 CON 21 8.32 506295 41 35 24 19.1 101.9 
297 PRO 21 20.38 318792 23 43 34 27.3 102.2 
298 CON 21 12.715 572992 33 33 34 23.2 101.8 
300 PRO 21 13.74 510004 24 45 31 25.4 102.1 
301 CON 21 12.89 631701 31 38 31 27.3 102.3 
302 PRO 21 11.26 652467 23 37 40 20 102 
304 CON 21 9.936 1531000 40 34 26 28.6 101.8 
291 PRO 28 20.74 406822 37 38 25 30.4 102.2 
292 CON 28 23.73 613285 22 47 31 30.9 102 
293 PRO 28 9.03 553158 26 42 32 28.5 101.9 
295 PRO 28 19.92 376734 25 45 30 36.8 101.8 
296 CON 28 24.44 412458 22 50 28 37.7 102.4 
297 PRO 28 16.43 382365 28 45 27 32.7 102.1 
298 CON 28 12.24 724330 18 37 45 27.7 101.6 
300 PRO 28 16.93 380614 21 47 32 25.4 102.6 
301 CON 28 22.21 675596 27 45 28 35.4 102 
302 PRO 28 16.21 575630 22 37 41 31.3 101.6 
304 CON 28 18.22 796323 40 36 24 35 102.3 
291 PRO 35 23.15 296430 30 32 37 59.1 102.3 
292 CON 35 20.59 827270 28 40 32 37.8 102.2 
293 PRO 35 16.91 572448 25 38 37 34.1 102.4 
295 PRO 35 7.65 424796 33 28 39 42.2 102 
296 CON 35 16.43 425028 33 40 27 44.1 101.8 
297 PRO 35 15.14 401008 34 37 29 41.8 102.3 
298 CON 35 19.18 715597 30 40 30 36.8 102 
300 PRO 35 15.62 344833 26 38 36 26.3 102.1 
301 CON 35 11.88 682931 30 34 46 38.2 101.4 
302 PRO 35 17.69 419971 24 40 36 30 102.4 
304 CON 35 18.92 653404 40 35 25 40 102.2 
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Scope and Method of Study: The purpose of this study was to investigate effect of 
       probiotics as dietary supplement in three to four month-old Holstein calves on their  
       local and systemic immune responses. Probiotic bacteria are microorganisms that  
       have beneficial effects on the physiology and pathology of their host animals. Their  
       effects on intestinal microflora may play a role in improving animal health.  One of  
       their putative effects is the modulation of the immune function.  Probiotics have been  
       shown to affect the innate and both the cellular and the humoral arms of the immune  
       system. In this study, Lactobacillus acidophilus was administered orally to six calves  
       daily for 35 days at the rate of 109 colony-forming units per animal. Five other calves  
       were not given the bacteria and served as controls. 
 
Findings and Conclusions: I observed that there was no significant difference observed in  
       phagocytic activity of immune cells isolated from animals fed on probiotics and the 
       controls.  ELISA measurements of serum IgA concentrations of animals fed on  
       probiotics and their controls showed no significant difference.  Pro-inflammatory 
cytokine gene assay, by semi-quantitative RT-PCR also yielded result of no 
significant difference between the two groups of animals suggesting that the probiotic 
did not have effect on their regulation. Therefore, I concluded that, at the rate of 
feeding healthy 3 to 4- month old calves with at least 109 colony-forming units of 
bacteria, no key immunological function is enhanced.  Either the bacteria had 
difficulty in establishing and colonizing the gastrointestinal tract, or the numbers of 
bacteria fed  to the animals were low such that no microfloral balance was created 
leading to no beneficial effects being conferred to the animals.    
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